Abstract
BackgroundPsoriasis is a chronic immune-mediated inflammatory skin disease without effective treatment. The utilization of all trans-retinoic acid (TRA) and betamethasone (BT) for the treatment of psoriasis is still facing difficulties, due to their relatively poor stability, limited skin permeation, and systemic side effects. Flexible liposomes are excellent in deeper skin permeation and reducing the side effects of drugs, which is promising for effective treatment of skin disorders. This work aimed to establish dual-loaded flexible liposomal gel for enhanced therapeutic efficiency of psoriasis based on TRA and BT.ResultsFlexible liposomes co-loaded with TRA and BT were successfully prepared in our study. The characterization examination revealed that flexible liposomes featured nano-sized particles (around 70 nm), high drug encapsulation efficiency (> 98%) and sustained drug release behaviors. Flexible liposomes remarkably increased the drug skin permeation and retention as compared with free drugs. Results on HaCaT cells suggested that flexible liposomes were nontoxic, and its cellular uptake has a time-dependent manner. In vivo studies suggested the topical application of TRA and BT dual-loaded liposomal gel had the best ability to reduce the thickness of epidermal and the level of cytokines (TNF-α and IL-6), largely alleviating the symptoms of psoriasis.ConclusionsFlexible liposomal gel dual-loaded with TRA and BT exerted a synergistic effect, which is a promising topical therapeutic for the treatment of psoriasis.
Highlights
Psoriasis is considered to be the most prevalent chronic immune-mediated inflammatory skin disease [1]
Previous study has suggested that trans retinoic acid (TRA) could inhibit the inflammatory response by largely reducing the expression levels of proinflammatory cytokines (e.g., IL-6, ICAM-1 and HLA-DR), which is beneficial for psoriatic treatment [15,16,17]
Characterization of flexible liposomes The characterization of liposome-based delivery systems is fundamental, since it commonly affects the biopharmaceutical behaviors of the drugs in the delivery process
Summary
Psoriasis is considered to be the most prevalent chronic immune-mediated inflammatory skin disease [1]. This disease is commonly expressed as the long-lasting presence of. Exploring a novel topical treatment with enhanced therapeutic effect is largely needed for patients who have psoriasis. All-trans retinoic acid (TRA), a member belongs to retinoid family, is frequently used for the treatment of skin disorders, such as acne, skin carcinoma, wound recovery, and psoriasis [10,11,12]. Psoriasis is a chronic immune-mediated inflammatory skin disease without effective treatment. The utilization of all trans-retinoic acid (TRA) and betamethasone (BT) for the treatment of psoriasis is still facing difficul‐ ties, due to their relatively poor stability, limited skin permeation, and systemic side effects.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
